NIH Grant Awards Stall as Trump-Era Budget Blocks Create Unprecedented Backlogs

Researchers Face Cliff as NIH Funding Notices Plunge 89%

When the lifeblood of biomedical research dries up, the effects are felt instantly in labs all across the country. Over the past 13 months, the National Institutes of Health (NIH) has posted just 84 Notices of Funding Opportunities (NOFOs)—down nearly 89% from the previous year’s 787—leaving hundreds of teams with no clear path forward for research proposals or program renewals. “Many programs are in limbo and may be pushed back a year or two. For some that will be devastating,” warns former NIH official Jennifer Troyer. For researchers and organizations dependent on steady competition cycles, this is more than a delay—it's a direct threat to jobs, experiments, and future advancements.

How White House Spending Blocks Created a Perfect Storm

The unprecedented slowdown is not simply a matter of administrative backlog. After signing the FY2026 budget on Feb. 3, President Trump’s administration—through the Office of Management and Budget (OMB)—imposed new controls freezing research spending beyond salaries and operational essentials for 30 days. Even with Congress’s approval, disbursement for research programs hinges on complex “spend plans,” which can stretch the review process to a crawl. This echoes last year’s standoffs, when OMB blocks lasted months, and only congressional pressure unjammed the funds.[1]

Compounding matters, the 43-day federal shutdown last fall forced NIH to triage awards using leftover funds from interim resolutions. For some institutes, including the National Cancer Institute (NCI) with its $7.3 billion budget, a new 16-step approval process has forced one-year extensions—delaying plans until FY2027. This has left not only NOFOs but also major grant renewals for opioid, Alzheimer’s, and other congressional priorities on an indefinite timetable.

Real-World Impact: Experiments Halted and Labs in Jeopardy

Across the US, postdocs are losing job security, experiments are stalled midstream, and academic centers are reporting furloughs. According to research analysis by Jeremy Berg, the pace of new and competing NIH awards is just one-third of normal, with only ~800 out of 2,400 typical awards released so far in FY2026. When funds do move, it’s often at the expense of long-term planning: programs are extended into the next fiscal year, some researchers must reapply or shift projects to "mismatched" mechanisms, and any money left unspent by fiscal year-end could be lost to the Treasury.

Labs working in fields like DEI, HIV, LGBTQ+ health, and broader public health priorities faced particularly sharp disruptions when NIH announced late last year it would not renew DEI-focused grants after current terms expire—prompted by both ongoing policy priorities and court decisions. While legal action on Dec. 29 forced NIH to reinstate 499 of 528 frozen grants, the broader pool of 5,000+ pending applications awaits full review and decisions by July 31, 2026.

What Nonprofits and Small Businesses Need to Know

It’s not just academic labs bearing the brunt: nonprofits running health initiatives and small businesses in the SBIR pipeline are now caught in this freeze, too. Any organization waiting on R01, U-series, or other major NIH vehicles should brace for prolonged limbo—unless their project is mission-critical or flagged in a spend plan, expect a wait well into summer, if not FY2027. Even after approvals, NOFOs may be broader than before, requiring quick adaptation of proposal content and partnerships. Limited advance notice means competition will intensify for every posted opportunity, and new applicants need to carefully monitor both the NIH eRA Commons and the relevant NIH Institute and Center pages for sudden openings and accelerated timelines.

Institutes may also favor short-term renewals or partial-year funding to avoid lapses or recapture by the Treasury, further squeezing project timelines. Small businesses that rely on predictable SBIR/STTR cycles should prepare for delays and consider alternate funders or bridge financing to keep staff and development on track.

What Researchers Should Do While Funding Is Frozen

Stay proactive, not passive:

• Monitor NOFOs daily—the backlog means new opportunities may be released with little notice and quick turnaround times
• Stay connected to program officers for updates on the status of pending awards, clarity on spend plan approvals, and institute-specific processes
• Plan for bridge funding or internal reallocations to keep critical work moving if awards are delayed
• Document impacts—delayed experiments, furloughs, and lost outputs—as some advocates and scientific societies are gathering evidence to press for regulatory relief or funding catch-ups once the logjam clears

Any proposals or renewal cycles forecasted (but not posted) for 2024–2025 are at high risk; consider alternative sponsors or partners if possible. DEI, HIV, LGBTQ+, and other "targeted" areas remain especially vulnerable to further delay or cancelation.

What Comes Next as September Deadline Approaches

Pressure is now building from advocacy groups and state attorneys general, and legal battles have forced some grant reinstatements. But with September 30 marking the end of the fiscal year, there is little confidence NIH can catch up fully. Political winds could shift with congressional intervention—last year Republican pushback unblocked some funds—but as of now, strong leadership action is missing. Labs and organizations should watch for possible “emergency” NOFO rounds or compressed review cycles, but also for further restrictions as long as the current approval processes remain in place.

As the nation's main biomedical funder faces its most severe disruption in recent memory, researchers and organizations must stay nimble—tracking updates and preparing for abrupt changes—to protect their work and missions in the grantmaking wilderness. For those seeking clarity and competitive opportunities in this volatile environment, resources like Granted AI can offer vital real-time monitoring and strategic support.